SWK (SWKH) Q2 2025 earnings summary

Executive summary

• Completed sale of the majority of royalty assets and MOD3 subsidiary assets, simplifying operations and focusing on specialty finance and life science lending.

• Q2 2025 GAAP net income was $3.5 million, down from $3.7 million in Q2 2024; adjusted non-GAAP net income rose to $4.6 million from $2.6 million year-over-year.

• Paid a $4.00 per share special dividend, returning $49 million to shareholders, and repurchased 58,954 shares for $0.9 million in Q2 2025, with year-to-date repurchases totaling $3 million.

• Revenue for Q2 2025 was $10.1 million, down from $10.8 million in Q2 2024, mainly due to the royalty portfolio sale, partially offset by higher pharmaceutical development revenue.

• Remaining assets include $234 million in gross performing first-lien term loans (14.1% yield), $12 million in non-performing reorganization royalties, $5 million in public equity warrants, and 11 private warrants/earnouts carried at $0 for GAAP.

Financial highlights

• Six-month revenue was $21.9 million, slightly down from $22.2 million year-over-year; net income for the six months rose to $8.1 million from $4.1 million.

• GAAP book value per share was $20.23 as of June 30, 2025, down 11% year-over-year, but up 6.8% when adjusted for the $4.00 dividend.

• Non-GAAP tangible financing book value per share was $18.47, up 11.7% year-over-year after the $4 per share special dividend.

• Operating expenses for Q2 2025 were $5.4 million, down from $9.9 million in Q2 2024.

• Allowance for credit losses decreased to $8.8 million from $11.2 million at year-end.

Outlook and guidance

• Management views Q2 2025 results as a reasonable run rate for future business performance and expects positive cash flows from finance receivables and investments for the remainder of 2025.

• Normalized SG&A expected to be around $2 million per quarter, barring one-off legal expenses.

• Management continues to evaluate new investment opportunities but does not assume near-term repayments from borrowers.

• Focus remains on financing innovative life science companies and supporting existing performing borrowers.